We are a drug discovery company
with the sole corporate focus on obesity and metabolic disorders.
Obesity has reached epidemic proportions and for which no good medical therapies currently exists. In the US alone, more than 100 million adults are obese and the direct costs to the healthcare system amount to 6% of the total healthcare budget - and indirect costs are estimated to be around US$50 billion.
(source: WTO,2003)
• Blockbuster potential in the acquired patents and patent applications, which could lead to a drug to cure metabolic disorders.
• Rapid advancements reducing time to market and accelerating milkestone payments and royalty streams
- One diabetes target for which patient recruitment for phase 2a has commenced
- One obesity in preclinical trials
• A world-class management team of experts with more than a century of combined experience in obesity and metabolic disorder research, complemented by an advisory board with recognized as outstanding international scientists.
• Access to international high quality cost-efficient research engines, benefiting from the excess capacity in the sector. Research cooperation agreements with leading R&D Service Providers, research institutions and universities in the US, Canada, India and Europe (UK, France,Denmark).
• Unique cost-efficient technology and patent acquisition strategy for proprietary intellectual property (IP) from identified companies, government institutions and universities, paid via milestone-dependent research collaboration and grants.
• IP acquisitions pending with leading universities and institutions in Europe, China and India, including two already identified cost-efficient technology targets. Flexible execution strategy as technology can be on "loan" to Bridge BioResearch for evaluation before substantial investment is committed.
